News | July 03, 2021
Solara announces restoration of CEP for ranitidine hydrochloride
Ranitidine Hydrochloride is an important product for Solara and is manufactured at its Cuddalore site
Ranitidine Hydrochloride is an important product for Solara and is manufactured at its Cuddalore site
The company has posted net profit / (loss) of Rs.5.33 crores for the 12 months period ended March 31, 2021
The five pharma companies have entered into a collaboration agreement, wherein the parties will jointly sponsor, supervise and monitor the clinical trial in India
It is also used for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection.
The company is exploring all legal options to challenge the award.
These five oxygen plants with a total capacity of 3,840 cubic meters of oxygen per day have been donated to Madhya Pradesh, Maharashtra, and Gujarat
With the acquisition of these further shares, TWPL has now become company's subsidiary.
It is expected that the drug substance would be available from August 2021 which will be supplied back to Bharat Biotech for producing COVAXIN
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
Subscribe To Our Newsletter & Stay Updated
